FNY Managed Accounts’s Aratana Therapeutics, Inc. PETX Stock Holding History

FNY Managed Accounts’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$2K	Hold	500	–	–	﹤0.01%	470
2017 Q4	$2K	Sell	500 -1,500	-75%	-$9.18K	﹤0.01%	537
2017 Q3	$12K	Buy	+2,000	New	+$12.7K	0.02%	423
2016 Q2	–	Sell	-2,500	Closed	-$13.8K	–	465
2016 Q1	$13.8K	Buy	+2,500	New	+$9.4K	0.02%	213
2015 Q3	–	Sell	-23,000	Closed	-$348K	–	635
2015 Q2	$348K	Buy	23,000 +4,400	+24%	+$63.5K	0.41%	51
2015 Q1	$298K	Buy	+18,600	New	+$331K	0.25%	58

Other funds holding PETX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

FNY Managed Accounts's PETX Position: Q1 2018 in Review

FNY Managed Accounts held its Aratana Therapeutics, Inc. (PETX) position steady in Q1 2018 at 500 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

FNY Managed Accounts first reported a position in PETX in Q1 2015 and has held it in 6 quarters since. The position peaked at $348K in Q2 2015. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

FNY Managed Accounts held 500 shares of Aratana Therapeutics, Inc. worth $2K as of Q1 2018.
FNY Managed Accounts left its Aratana Therapeutics, Inc. share count unchanged in Q1 2018.
Aratana Therapeutics, Inc. made up ﹤0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #470 holding.
FNY Managed Accounts first reported a position in Aratana Therapeutics, Inc. in Q1 2015 and has held it in 6 quarters since.
FNY Managed Accounts's Aratana Therapeutics, Inc. position peaked at $348K in Q2 2015.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.